FLGT Fulgent Genetics, Inc.

CIK 0001674930 17 ready 8-Ks latest June 1, 2026, 7:07 PM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline

Ready 8-Ks 17

Latest filing June 1, 2026, 7:07 PM ET

Top materiality 0.75

Event mix earnings ×9 · other_material ×6 · m_and_a ×2

Sentiment 6 pos · 1 neg · 10 neu

Recent 8-K filings for FLGT

Highest-materiality recent filing

Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share

February 27, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.
GAAP net loss $23.4M ($0.76 loss per share) in Q4; full-year GAAP loss $60.5M ($1.97 per share).

Read filing →

June 1, 2026, 7:07 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026

FID-007 + cetuximab showed 61.9% objective response rate in PD-1 resistant R/M HNSCC.
May 21, 2026, 5:04 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Fulgent reports FID-007 + cetuximab Phase 2 HNSCC data: 60% ORR, 7.2 mo mPFS

Interim Phase 2 data: ORR 60% (58% Arm A, 61% Arm B); mPFS 7.2 months across 42 evaluable patients.
May 14, 2026, 4:27 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01

Fulgent Genetics shareholders approve 2026 equity plan authorizing 2M new shares

2026 Equity Incentive Plan replaces prior 2016 plan; authorizes 2,000,000 new shares plus up to 1,500,000 from forfeited awards.
May 1, 2026, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Q1 2026: GAAP EPS -$0.80, revenue $71.1M, reiterates FY2026 guidance

GAAP net loss of $24.8M ($0.80/share); non-GAAP loss of $11.0M ($0.36/share).
March 17, 2026, 7:59 PM ET M&A materiality 0.70 neutral item 1.01 item 2.01 item 7.01 item 9.01 ◈ M&A Transactions ×2

Fulgent Genetics completes acquisitions of Bako Diagnostics and StrataDx for ~$56.9M cash

Total combined purchase price approximately $56.9 million in cash, subject to post-closing adjustments.
February 27, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share

Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.
December 22, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 8.01 item 9.01

Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total

Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.
November 7, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Fulgent Genetics Q3 revenue $84.1M (+17% YoY), raises FY guidance, non-GAAP EPS $0.14

Revenue $84.1M, up 17% YoY; raised full-year 2025 revenue guidance to $325.0M.
October 20, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Fulgent reports Phase 2 FID-007 combo data: 51% ORR, PFS 7.8 months in R/M HNSCC

Preliminary Phase 2 data for FID-007 + cetuximab in 1L-2L R/M HNSCC; 39 patients randomized.
August 1, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Fulgent Q2 core revenue $81.7M (+16% YoY); raises FY2025 guidance to $320M

Core revenue $81.7M, up 16% YoY; total revenue $81.8M.
May 15, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Fulgent Genetics elects directors, ratifies auditor, approves say-on-pay at 2025 meeting

All four director nominees elected: Ming Hsieh (19.3M for), Michael Nohaile (16.0M for), Regina Groves (14.3M for), Linda Marsh (13.8M for).
May 2, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Fulgent Q1 core revenue $73.5M (+16% YoY); GAAP loss $0.37/share; reiterates FY25 guidance

Core revenue of $73.5M, up 16% YoY; GAAP net loss of $11.5M ($0.37 loss per share).
February 28, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M

Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.
November 8, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Fulgent Q3 core rev $71.7M (+9% YoY), GAAP loss $0.48, non-GAAP EPS $0.31; guides FY core rev $280M

Total revenue $71.7M, core revenue (ex-COVID) $71.7M, up 9% YoY.
August 2, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Fulgent Q2 core revenue $70.2M (+5% YoY); GAAP loss $0.29/share improves EPS guidance

Total revenue $71.0M; core revenue $70.2M (+5% YoY).
May 16, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×3

Fulgent Genetics announces 2024 annual meeting voting results

All four director nominees elected: Ming Hsieh, Michael Nohaile, Regina Groves, Linda Marsh (votes for ranged ~15.8M to 20.0M).
May 3, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Q1 2024 core revenue $63.2M (+1% YoY), GAAP loss $0.45/share, reiterates FY guidance

Total revenue $64.5M; core revenue $63.2M (+1% YoY); FY2024 core revenue guidance reiterated at $280M.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.65 · Most common event earnings

6 positive 1 negative 10 neutral

source · FLGT on sec.gov